The global acute kidney injury treatment market was valued at US$ 3.6 Bn in 2024 and is projected to reach US$ 8.2 Bn by 2035, registering a CAGR of 7.8% from 2025 to 2035. The market is driven by the growing incidence of kidney injuries due to rise in the prevalence of chronic disorders such as hypertension, diabetes, and others.
These chronic conditions lead to rise in various forms of acute kidney injury such as septic shock, increased consumption of nephrotoxic drugs, cardiac surgeries, kidney and stem cell transplantation, hyperkalemia, Allergic interstitial nephritis, and others. These are some of the major causes which has further resulted in driving the overall market.
The acute kidney injury (AKI) treatment market heavily depends on research and development (R&D) efforts. The rising number of AKI cases from critical conditions and chronic diseases in aging population creates higher demand for new treatment solutions. Investment in R&D has resulted in progress in early detection methods along with breakthroughs in drug treatments and enhanced dialysis procedures which together transform the AKI treatment landscape.
For instance, in August 2024, Novartis, announced that the U.S. Food and drug administration (FDA) granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.
This is generally defined as a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g. Fabhalta specifically targets the alternative complement pathway of the immune system. When overly activated in the kidneys, the complement system is thought to contribute to the pathogenesis of IgAN.
Acute kidney injury (AKI) is a sudden episode of kidney failure/damage that can range from minor loss of kidney functions to complete kidney failure. Diarrhea, feeling sick or being sick, dehydration, drowsiness, and confusion are some of the common symptoms of acute kidney injuries.
Treatment for kidney injuries primarily depends on the cause and extent of the injury. Experimental treatments for the management of AKIs primarily comprise vasoactive peptides, growth-factors, endothelin inhibitors, adhesion molecules, and bio-artificial kidneys. Aminophylline has also been used experimentally for prophylaxis, specifically against renal failure (RF).
| Attribute | Detail |
|---|---|
| Acute Kidney Injury Treatment Market Drivers |
|
Acute Kidney Injury (AKI) now poses a major threat to global health as its increasing occurrence creates substantial challenges for healthcare systems. AKI manifests as an abrupt reduction in kidney function that occurs due to various triggers like sepsis, cardiovascular diseases, major surgical operations, and nephrotoxic drugs.
Advanced AKI treatment solutions are in higher demand because of the increasing number of elderly patients, diabetics, and hypertensive patients who are at high risk. The report examines how market growth is stimulated by rising AKI cases in high-risk groups through analysis of statistical data and market drivers which present opportunities to stakeholders.
For instance, as per an article published by Clinical Kidney Journal in 2021, the incidence of acute kidney injury (AKI) among inpatients worldwide varies from 0.7% to 31.0%, with intensive care unit (ICU) patients exceeding 50%. The mortality rate related to AKI is 23.0%, which increases to 49.4% in those requiring renal replacement therapy.
Patients who have survived AKI with complete kidney function recovery are reported to have a better long-term prognosis, but many patients experience significant irreversible nephron loss and subsequently develop chronic kidney disease (CKD). Indeed, 20-50% of AKI patients develop progressive CKD, while 3-15% reach end-stage kidney disease (ESKD) all related with increased mortality.
With regards to the actual pathologies of the critical patient, sepsis stands out as the main cause of acute kidney dysfunction, with an incidence of 15-20%. Regarding the non-septic AKI, it has a higher mortality rate, a longer stay in the ICU, but a better rate of renal recovery, with similar continuous renal replacement therapy (CRRT) needs.
Moreover, according to BioMed Central Ltd survey published in August 2023, acute kidney injury is a common in-hospital complication. In the general population, the reported incidence of hospital-acquired AKI varies between seven and 18% depending on the burden of disease and age of the studied population.
Global hospital admission rates are on the rise, which subsequently fuels the expansion of the acute kidney injury treatment market. Acute kidney injury represents an abrupt deterioration in kidney function that frequently appears in patients who are hospitalized due to numerous medical conditions along with surgical procedures or medication-related issues.
The growing number of hospital admissions driven by chronic diseases and an aging population along with healthcare advancements leads to an increased demand for AKI treatment. This article examines how rising hospital admissions contribute to greater demand for acute kidney injury treatment.
Acute kidney injury (AKI) develops in 8.0% to 16.0% of hospital admissions. These patients exhibit a 4- to 10-fold increase in mortality and prolonged hospital stays. There is a dearth of information on the economics of AKI, especially in critically ill patients whose health-care costs are already high. Inpatient AKI affects an estimated 498,000 patients in the United States with its annual cost from US$ 4.7 to US$ 24.0 Bn.
Average patient costs of AKI in the intensive care unit are generally double than those of non-AKI patients. AKI severity portends a higher cost. Total hospital costs in patients with AKI range from US$ 29,700.0 in cardiac surgery patients to US$ 80,400.0 in cardiogenic shock.
Incremental increases of cost range from US$ 9,400.0 in major surgery patients and up to US$ 81,000.0 in non-surviving dialysis patients. The enormity of the clinical and economic impact of AKI should be a call to action by pharmacists to expeditiously select patient-specific therapies to prevent and treat AKI, and thus reduce its economic burden on an already fragile health-care system.
Moreover, according to the Center for Medicare and Medicaid, AKI is common in the intensive care unit (ICU), which affects over 50% of patients during the first week of ICU admission. There is also an estimated 7-fold increased mortality risk as compared to patients without AKI. Consequences of AKI include the need for renal replacement therapy (RRT) and the progression to chronic kidney disease (CKD) in about 20% of patients and a decreased quality of life.
Intravenous (IV) crystalloid solutions are fluids composed of water and electrolytes that are commonly used for fluid resuscitation, hydration, and electrolyte balance in acute kidney injury treatment. They are first-line therapy for hypovolemia (low blood volume), dehydration, and shock-related acute kidney injury treatment. They are the first-line therapy for hypovolemia, dehydration, and septic acute kidney injury.
The role of IV Crystalloid solution includes fluid resuscitation in hypovolemic acute kidney injury, managing septic shock, electrolyte & acid-base balance, preventing contrast-induced nephropathy, and others. Some of the common IV crystalloid solutions used in acute kidney injury management includes Normal Saline (0.9% NaCl), Lactated Ringer’s (LR), Plasma-Lyte, Dextrose 5% in water (D5W), 0.45% NaCl, 3% NaCl (Hypertonic Saline), and others.
In the acute kidney injury treatment market, the IV crystalloid solution drug therapy segment is dominating the overall segment, owing to the increasing acute kidney injury incidence in ICUs and critical care settings. Moreover, it is the first-line therapy for one of the underlining causes for AKI such as Hypovolemia, and Shock-related AKI.
IV crystalloids (Normal Saline, Lactated Ringer’s, Plasma-Lyte) are the first-line treatment for restoring circulating blood volume and preventing kidney damage in conditions such as Septic shock, hypovolemic shock, cardiogenic shock, cardiogenic shock, and severe dehydration. The IV crystalloid solution market in AKI treatment is expanding due to its critical role in fluid resuscitation, shock management, contrast-induced AKI prevention, and sepsis treatment.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
The rising prevalence of acute kidney injury treatment amongst the general population is one of the main causes of North America's supremacy. AKI is prevalent among hospitalized patients, particularly in intensive care units (ICUs), where renal impairment is often exacerbated by sepsis, major surgeries, and serious illnesses.
The risk of acute kidney injury treatment is further increased by the growing prevalence of chronic diseases such diabetes, high blood pressure, and cardiovascular disorders in North America. Acute kidney injury treatment is a major public health concern in the United States and Canada as lifestyle factors like obesity and sedentary behavior have led to the rising incidence of these chronic diseases.
Another important issue is the growing number of old people in the area. This is because aging population is more vulnerable to acute kidney injury treatment due to comorbidities, decreased kidney function, and increased exposure to nephrotoxic drugs.
Another important factor in North America's dominant position in the acute kidney injury treatment industry is the availability of cutting-edge healthcare infrastructure. The U.S. holds a major market share in North America’s acute kidney injury treatment market, primarily due to its robust healthcare ecosystem, significant investments in biotechnology, and pioneering role in research and development.
In September 2024, Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted 100% approval to FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression.
FILSPARI was granted accelerated approval in February 2023 based on the surrogate marker of proteinuria. 100% approval is based on positive long-term confirmatory results from the PROTECT Study demonstrating that FILSPARI significantly slowed kidney function’s decline over two years as compared to irbesartan.
Leading companies are partnering with hospitals, urology clinics, long surgery centers, and research institutes to improve their acute kidney injury treatment drugs and expand distribution.
AM-Pharma, Aptabio Therapeutics, Arch Biopartners, Novartis AG, Guard Therapeutics, Renibus Therapeutics, Mission Therapeutics, Unicycive Therapeutics Inc., Baxter International Inc., ICU Medical, B. Braun Melsungen AG, Fresenius Kabi, Amanta Healthcare, Pfizer, Inc., and Sanofi S.A., are some of the prominent acute kidney injury treatment market players operating in the industry
Each of these players has been profiled in the acute kidney injury treatment market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2024 | US$ 3.6 Bn |
| Forecast Value in 2035 | More than US$ 8.2 Bn |
| CAGR | 7.8% |
| Forecast Period | 2025-2035 |
| Historical Data Available for | 2020-2024 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global acute kidney injury treatment market was valued at US$ 3.6 Bn in 2024.
Acute kidney injury treatment business is projected to cross US$ 8.2 Bn by the end of 2035.
Rising Incidence of acute kidney injury due to the growing high risk patient population, and growing research and development activities.
The CAGR is anticipated to be 7.8% from 2025 to 2035.
North America is expected to account for the largest share from 2025 to 2035.
AM-Pharma, Aptabio Therapeutics, Arch Biopartners, Novartis AG, Guard Therapeutics, Renibus Therapeutics, Mission Therapeutics, Unicycive Therapeutics Inc., Baxter International Inc., ICU Medical, B. Braun Melsungen AG, Fresenius Kabi, Amanta Healthcare, Pfizer, Inc., and Sanofi S.A.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Acute Kidney Injury Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, 2020-2035
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product & Brand Analysis
5.3. Regulatory Scenario by Country/Region
5.4. Disease Prevalence & Incidence Rate globally with key countries
5.5. Mortality Rate by Type of AKI- globally with key Countries
5.6. Emerging Trends - By Type of AKI
5.6.1. Investigational New Drug (IND) - MTX652
5.6.2. Extracellular Vesicle (EV) Therapy for AKI using iNPC-derived EV
5.6.3. Biomarkers for Early AKI Diagnosis
5.6.4. Continuous Renal Replacement Therapy (CRRT) Advancements
5.6.5. Gene Therapy in Kidney Repair
5.6.6. Prevention Of NephroToxin induced Acute Kidney injury with Cilastatin
5.6.7. Drug Candidate For the Treatment of AKI - UNI-494
5.6.8. RMC-035-IND (Investigational New Drug)
5.6.9. Artificial Intelligence in AKI
5.6.10. Mesenchymal Stem Cell Therapy
5.7. Benchmarking of the Products Offered by the Competitors
5.8. Porter's Five Forces Analysis
5.9. PESTEL Analysis
5.10. Insights on Restraints/Challenges & Major Factors for Considerations & Business Models for New Entrants (Mainly OEMs)
6. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, By Drug Therapy
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Therapy, 2020-2035
6.3.1. Vasoconstrictor Agents
6.3.2. Inotropic Drugs
6.3.3. Diuretics
6.3.4. Intravenous (IV) Crystalloid Solution
6.3.5. Immunosuppressive Drugs
6.3.6. Others
6.4. Market Attractiveness By Drug Therapy
7. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, By Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Type, 2020-2035
7.3.1. Pre-renal Acute Kidney Injury
7.3.2. Intrinsic renal Acute Kidney Injury
7.3.3. Post-renal Acute Kidney Injury
7.4. Market Attractiveness By Type
8. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, By Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Distribution Channel, 2020-2035
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness By Distribution Channel
9. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Region
10. North America Acute Kidney Injury Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Drug Therapy, 2020-2035
10.2.1. Vasoconstrictor Agents
10.2.2. Inotropic Drugs
10.2.3. Diuretics
10.2.4. Intravenous (IV) Crystalloid Solution
10.2.5. Immunosuppressive Drugs
10.2.6. Others
10.3. Market Value Forecast By Type, 2020-2035
10.3.1. Pre-renal Acute Kidney Injury
10.3.2. Intrinsic renal Acute Kidney Injury
10.3.3. Post-renal Acute Kidney Injury
10.4. Market Value Forecast By Distribution Channel, 2020-2035
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast By Country, 2020-2035
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Therapy
10.6.2. By Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Acute Kidney Injury Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Therapy, 2020-2035
11.2.1. Vasoconstrictor Agents
11.2.2. Inotropic Drugs
11.2.3. Diuretics
11.2.4. Intravenous (IV) Crystalloid Solution
11.2.5. Immunosuppressive Drugs
11.2.6. Others
11.3. Market Value Forecast By Type, 2020-2035
11.3.1. Pre-renal Acute Kidney Injury
11.3.2. Intrinsic renal Acute Kidney Injury
11.3.3. Post-renal Acute Kidney Injury
11.4. Market Value Forecast By Distribution Channel, 2020-2035
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast By Country / Sub-region, 2020-2035
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Therapy
11.6.2. By Type
11.6.3. By Distribution Channel
11.6.4. By Country / Sub-region
12. Asia Pacific Acute Kidney Injury Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Therapy, 2020-2035
12.2.1. Vasoconstrictor Agents
12.2.2. Inotropic Drugs
12.2.3. Diuretics
12.2.4. Intravenous (IV) Crystalloid Solution
12.2.5. Immunosuppressive Drugs
12.2.6. Others
12.3. Market Value Forecast By Type, 2020-2035
12.3.1. Pre-renal Acute Kidney Injury
12.3.2. Intrinsic renal Acute Kidney Injury
12.3.3. Post-renal Acute Kidney Injury
12.4. Market Value Forecast By Distribution Channel, 2020-2035
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast By Country / Sub-region, 2020-2035
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Therapy
12.6.2. By Type
12.6.3. By Distribution Channel
12.6.4. By Country / Sub-region
13. Latin America Acute Kidney Injury Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Therapy, 2020-2035
13.2.1. Vasoconstrictor Agents
13.2.2. Inotropic Drugs
13.2.3. Diuretics
13.2.4. Intravenous (IV) Crystalloid Solution
13.2.5. Immunosuppressive Drugs
13.2.6. Others
13.3. Market Value Forecast By Type, 2020-2035
13.3.1. Pre-renal Acute Kidney Injury
13.3.2. Intrinsic renal Acute Kidney Injury
13.3.3. Post-renal Acute Kidney Injury
13.4. Market Value Forecast By Distribution Channel, 2020-2035
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast By Country / Sub-region, 2020-2035
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Therapy
13.6.2. By Type
13.6.3. By Distribution Channel
13.6.4. By Country / Sub-region
14. Middle East & Africa Acute Kidney Injury Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Drug Therapy, 2020-2035
14.2.1. Vasoconstrictor Agents
14.2.2. Inotropic Drugs
14.2.3. Diuretics
14.2.4. Intravenous (IV) Crystalloid Solution
14.2.5. Immunosuppressive Drugs
14.2.6. Others
14.3. Market Value Forecast By Type, 2020-2035
14.3.1. Pre-renal Acute Kidney Injury
14.3.2. Intrinsic renal Acute Kidney Injury
14.3.3. Post-renal Acute Kidney Injury
14.4. Market Value Forecast By Distribution Channel, 2020-2035
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast By Country / Sub-region, 2020-2035
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Therapy
14.6.2. By Type
14.6.3. By Distribution Channel
14.6.4. By Country / Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2024)
15.3. Company Profiles
15.3.1. AM-Pharma
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Financial Overview
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Aptabio Therapeutics
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Financial Overview
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Arch Biopartners
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Financial Overview
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. Novartis AG
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Financial Overview
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Guard Therapeutics
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Financial Overview
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Renibus Therapeutics
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Financial Overview
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. Mission Therapeutics
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Financial Overview
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Unicycive Therapeutics Inc.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Financial Overview
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. Baxter International Inc.
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Financial Overview
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. ICU Medical
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Financial Overview
15.3.10.4. Business Strategies
15.3.10.5. Recent Developments
15.3.11. B. Braun Melsungen AG
15.3.11.1. Company Overview
15.3.11.2. Financial Overview
15.3.11.3. Financial Overview
15.3.11.4. Business Strategies
15.3.11.5. Recent Developments
15.3.12. Fresenius Kabi
15.3.12.1. Company Overview
15.3.12.2. Financial Overview
15.3.12.3. Financial Overview
15.3.12.4. Business Strategies
15.3.12.5. Recent Developments
15.3.13. Amanta Healthcare
15.3.13.1. Company Overview
15.3.13.2. Financial Overview
15.3.13.3. Financial Overview
15.3.13.4. Business Strategies
15.3.13.5. Recent Developments
15.3.14. Pfizer, Inc.
15.3.14.1. Company Overview
15.3.14.2. Financial Overview
15.3.14.3. Financial Overview
15.3.14.4. Business Strategies
15.3.14.5. Recent Developments
15.3.15. Sanofi S.A.
15.3.15.1. Company Overview
15.3.15.2. Financial Overview
15.3.15.3. Financial Overview
15.3.15.4. Business Strategies
15.3.15.5. Recent Developments
List of Tables
Table 01: Global Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Drug Therapy, 2020-2035
Table 02: Global Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Type, 2020-2035
Table 03: Global Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
Table 04: Global Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Region, 2020-2035
Table 05: North America - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, by Country, 2020-2035
Table 06: North America - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Drug Therapy, 2020-2035
Table 07: North America - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Type, 2020-2035
Table 08: North America - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
Table 09: Europe - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 10: Europe - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Drug Therapy, 2020-2035
Table 11: Europe - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Type, 2020-2035
Table 12: Europe - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
Table 13: Asia Pacific - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 14: Asia Pacific - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Drug Therapy, 2020-2035
Table 15: Asia Pacific - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Type, 2020-2035
Table 16: Asia Pacific - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
Table 17: Latin America - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 18: Latin America - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Drug Therapy, 2020-2035
Table 19: Latin America - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Type, 2020-2035
Table 20: Latin America - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
Table 21: Middle East & Africa - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 22: Middle East & Africa - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Drug Therapy, 2020-2035
Table 23: Middle East & Africa - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Type, 2020-2035
Table 24: Middle East & Africa - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
List of Figures
Figure 01: Global Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, 2020-2035
Figure 02: Global Acute Kidney Injury Treatment Market Value Share Analysis, By Drug Therapy, 2024 and 2035
Figure 03: Global Acute Kidney Injury Treatment Market Attractiveness Analysis, By Drug Therapy, 2025-2035
Figure 04: Global Acute Kidney Injury Treatment Market Revenue (US$ Bn), by Vasoconstrictor Agents, 2020-2035
Figure 05: Global Acute Kidney Injury Treatment Market Revenue (US$ Bn), by Inotropic Drugs, 2020-2035
Figure 06: Global Acute Kidney Injury Treatment Market Revenue (US$ Bn), by Diuretics, 2020-2035
Figure 07: Global Acute Kidney Injury Treatment Market Revenue (US$ Bn), by Intravenous (IV) Crystalloid Solution, 2020-2035
Figure 08: Global Acute Kidney Injury Treatment Market Revenue (US$ Bn), by Immunosuppressive Drugs, 2020-2035
Figure 09: Global Acute Kidney Injury Treatment Market Revenue (US$ Bn), by others, 2020-2035
Figure 10: Global Acute Kidney Injury Treatment Market Value Share Analysis, By Type, 2024 and 2035
Figure 11: Global Acute Kidney Injury Treatment Market Attractiveness Analysis, By Type, 2025-2035
Figure 12: Global Acute Kidney Injury Treatment Market Revenue (US$ Bn), by Pre-renal Acute Kidney Injury, 2020-2035
Figure 13: Global Acute Kidney Injury Treatment Market Revenue (US$ Bn), by Intrinsic renal Acute Kidney Injury, 2020-2035
Figure 14: Global Acute Kidney Injury Treatment Market Revenue (US$ Bn), by Post-renal Acute Kidney Injury, 2020-2035
Figure 15: Global Acute Kidney Injury Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 16: Global Acute Kidney Injury Treatment Market Attractiveness Analysis, By Distribution Channel, 2025-2035
Figure 17: Global Acute Kidney Injury Treatment Market Revenue (US$ Bn), by Hospital Pharmacies, 2020-2035
Figure 18: Global Acute Kidney Injury Treatment Market Revenue (US$ Bn), by Retail Pharmacies, 2020-2035
Figure 19: Global Acute Kidney Injury Treatment Market Revenue (US$ Bn), by Online Pharmacies, 2020-2035
Figure 20: Global Acute Kidney Injury Treatment Market Value Share Analysis, By Region, 2024 and 2035
Figure 21: Global Acute Kidney Injury Treatment Market Attractiveness Analysis, By Region, 2025-2035
Figure 22: North America - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, 2020-2035
Figure 23: North America - Acute Kidney Injury Treatment Market Value Share Analysis, by Country, 2024 and 2035
Figure 24: North America - Acute Kidney Injury Treatment Market Attractiveness Analysis, by Country, 2025-2035
Figure 25: North America - Acute Kidney Injury Treatment Market Value Share Analysis, By Drug Therapy, 2024 and 2035
Figure 26: North America - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Drug Therapy, 2025-2035
Figure 27: North America - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Type, 2025-2035
Figure 27: North America - Acute Kidney Injury Treatment Market Value Share Analysis, By Type, 2024 and 2035
Figure 29: North America - Acute Kidney Injury Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 30: North America - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Distribution Channel, 2025-2035
Figure 31: Europe - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, 2020-2035
Figure 32: Europe - Acute Kidney Injury Treatment Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 33: Europe - Acute Kidney Injury Treatment Market Attractiveness Analysis, by Country / Sub-region, 2025-2035
Figure 34: Europe - Acute Kidney Injury Treatment Market Value Share Analysis, By Drug Therapy, 2024 and 2035
Figure 35: Europe - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Drug Therapy, 2025-2035
Figure 36: Europe - Acute Kidney Injury Treatment Market Value Share Analysis, By Type, 2024 and 2035
Figure 37: Europe - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Type, 2025-2035
Figure 38: Europe - Acute Kidney Injury Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 39: Europe - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Distribution Channel, 2025-2035
Figure 40: Asia Pacific - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, 2020-2035
Figure 41: Asia Pacific - Acute Kidney Injury Treatment Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 42: Asia Pacific - Acute Kidney Injury Treatment Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
Figure 43: Asia Pacific - Acute Kidney Injury Treatment Market Value Share Analysis, By Drug Therapy, 2024 and 2035
Figure 44: Asia Pacific - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Drug Therapy, 2025-2035
Figure 45: Asia Pacific - Acute Kidney Injury Treatment Market Value Share Analysis, By Type, 2024 and 2035
Figure 46: Asia Pacific - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Type, 2025-2035
Figure 47: Asia Pacific - Acute Kidney Injury Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 48: Asia Pacific - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Distribution Channel, 2025-2035
Figure 49: Latin America - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, 2020-2035
Figure 50: Latin America - Acute Kidney Injury Treatment Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 51: Latin America - Acute Kidney Injury Treatment Market Attractiveness Analysis, by Country / Sub-region, 2025-2035
Figure 52: Latin America - Acute Kidney Injury Treatment Market Value Share Analysis, By Drug Therapy, 2024 and 2035
Figure 53: Latin America - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Drug Therapy, 2025-2035
Figure 54: Latin America - Acute Kidney Injury Treatment Market Value Share Analysis, By Type, 2024 and 2035
Figure 55: Latin America - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Type, 2025-2035
Figure 56: Latin America - Acute Kidney Injury Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 57: Latin America - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Distribution Channel, 2025-2035
Figure 58: Middle East & Africa - Acute Kidney Injury Treatment Market Value (US$ Bn) Forecast, 2020-2035
Figure 59: Middle East & Africa - Acute Kidney Injury Treatment Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 60: Middle East & Africa - Acute Kidney Injury Treatment Market Attractiveness Analysis, by Country / Sub-region, 2025-2035
Figure 61: Middle East & Africa - Acute Kidney Injury Treatment Market Value Share Analysis, By Drug Therapy, 2024 and 2035
Figure 62: Middle East & Africa - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Drug Therapy, 2025-2035
Figure 63: Middle East & Africa - Acute Kidney Injury Treatment Market Value Share Analysis, By Type, 2024 and 2035
Figure 64: Middle East & Africa - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Type, 2025-2035
Figure 65: Middle East & Africa - Acute Kidney Injury Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 66: Middle East & Africa - Acute Kidney Injury Treatment Market Attractiveness Analysis, By Distribution Channel, 2025-2035
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Acute Kidney Injury Treatment Market
